{"prompt": "['Product: MK-3475', '80', 'Protocol/Amendment No.: 604-09', 'Disease progression will be considered to be \"not confirmed\" at repeat imaging if ALL of the', 'following occur (as assessed by irRECIST):', 'Target lesion sum of diameters is <20% or <5 mm absolute increase compared to', 'nadir', 'Non-target disease resulting in initial PD is stable or qualitatively improved', 'New lesion resulting in initial PD is stable or qualitatively improved', 'No incremental new lesion(s) since last evaluation', 'No incremental new non-target lesion progression since last evaluation', 'If repeat imaging does not confirm PD per irRECIST as assessed by the local site', 'investigator and the subject continues to be clinically stable, treatment may continue and', 'follow the regular imaging schedule.', 'Disease progression will be considered to be \"confirmed\" at repeat imaging if ANY of the', 'following occur (as assessed by irRECIST):', 'Target lesion sum of diameters reaches or remains >20% and >5 mm absolute', 'increase compared to nadir', 'Non-target disease shows unequivocal progression, or the non-target disease resulting', 'in initial PD is qualitatively worse', 'New lesions appear for the first time, or the new lesions resulting in initial PD are', 'increased in size or number', 'If repeat imaging confirms PD due to any of the scenarios listed above, subjects will be', 'discontinued from study therapy.', 'Note: If a subject has confirmed radiographic progression (ie, 2 scans at least 4 weeks apart', 'demonstrating PD) per irRECIST, but the subject is achieving a clinically meaningful', 'benefit, and there is no further increase in the tumor burden at the confirmatory tumor', 'imaging, an exception to continue treatment may be considered following consultation with', 'the Sponsor (see Section 7.1.5.6 for details). In this case, if treatment is continued, tumor', 'imaging should continue to be performed following the intervals as outlined in the Trial', 'Flowchart (Section 6.0) and be submitted to the BICR.', 'MK-3475-604-09 Final Protocol', '23-Apr-2019', 'Confidential']['Product: MK-3475', '81', 'Protocol/Amendment No.: 604-09', 'If a subject develops a new brain metastasis during treatment, the following steps will be', 'taken:', 'Subjects with symptomatic brain metastases will be removed from study treatment.', 'Subjects with asymptomatic brain metastases (no need for steroids, no symptoms and', 'signs indicating clinically significant progression of disease, no decline in ECOG', 'performance status) can continue on study treatment under the following conditions:', 'If no immediate WBRT, both systemic lesions and brain lesions can be followed', 'by irRECIST.', 'If immediate WBRT is chosen, the brain lesions will be non-evaluable for', 'irRECIST.', 'Brain MRI will be required at each subsequent image assessment.', 'Additional details about irRECIST are referenced in the Merk Imaging Tip Sheet for', 'RECIST 1.1 and irRECIST.', 'MK-3475-604-09 Final Protocol', '23-Apr-2019', 'Confidential']['Product: MK-3475', '82', 'Protocol/Amendment No.: 604-09', 'Table 8', 'Imaging and Treatment After First Radiologic Evidence of Progressive Disease', 'Clinically Stable', 'Clinically Unstable', 'Imaging', 'Treatment', 'Imaging', 'Treatment', 'First radiologic', 'Repeat imaging at >4 weeks', 'May continue study', 'Repeat imaging at >4 weeks', 'Discontinue treatment', 'evidence of PD by', 'at site to confirm PD', 'treatment at the local site', 'to confirm PD per physician', 'RECIST 1.1', \"investigator's discretion\", 'discretion only (Imaging', '(modified to follow a', 'while awaiting confirmatory', 'should be reviewed by', 'maximum of 10 target', 'tumor imaging by site by', 'radiology as soon as', 'lesions and a', 'irRECIST.', 'possible.)', 'maximum of 5 target', 'lesions per organ),', 'which has been', 'verified by the BICR', 'Repeat tumor', 'No additional imaging', 'Discontinue treatment', 'No additional imaging', 'N/A', 'imaging confirms PD', 'required', '(exception is possible upon', 'required', 'irRECIST at the local', 'consultation with Sponsor)', 'site', 'Repeat tumor', 'Continue regularly', 'Continue study treatment at', 'Continue regularly', 'May restart study treatment', 'imaging shows SD,', 'scheduled imaging', \"the local site investigator's\", 'scheduled imaging', 'if condition has improved', 'PR or CR by', 'assessments', 'discretion', 'assessments', 'and/or clinically stable per', 'irRECIST at the local', \"investigator's discretion.\", 'site', 'Next tumor imaging should', 'occur according to the', 'regular imaging schedule', 'outlined in the protocol', 'Abbreviations: BICR=blinded independent central review; CR=complete response; irRECIST=immune-related Response Evaluation Criteria in Solid Tumors;', 'N/A=not applicable; PD=progressive disease; PR=partial response; SD=stable disease', 'MK-3475-604-09 Final Protocol', '23-Apr-2019', 'Confidential']\n\n###\n\n", "completion": "END"}